evipedia.aidev
← Back

Plasmalogens for Health & Longevity

Evidence Review created on 08/23/2026 using AI4L / Grok 4.5

Also known as: Vinyl Ether Phospholipids, Ether Phospholipids, Plasmenylethanolamine, Plasmenylcholine, Alkylglycerol Precursors

Motivation

Plasmalogens are unusual fats built into the membranes of brain, heart, and nerve cells. They carry a distinctive chemical bond that helps membranes stay flexible and may absorb damaging oxidants. Their levels fall with age, and they are often lower in people with memory loss and coronary disease. That pattern has made restoring them a live question in longevity circles.

Interest grew after blood tests linked lower circulating plasmalogens with more severe dementia, and after rare genetic diseases that block their production were shown to damage brain and bone. Almost no plant foods contain them. Protocols now use purified extracts from scallops or sea squirts, or laboratory-made precursors meant to rebuild the same fats from inside the cell. Product makers have funded most of the human trials, which is part of why the evidence needs a careful reading.

This review examines whether raising plasmalogen levels changes memory or heart-related blood fats, what is known about safety and sourcing, and how milligram marine extracts differ from gram-scale precursor oils.

Benefits - Risks - Protocol - Conclusion

High-level overviews of plasmalogen biology, disease associations, and restoration strategies.

No dedicated plasmalogen-supplementation content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine. Patrick’s site mentions plasmalogens only as a lipid class in a ketogenic-diet story, not as an intervention.

Grokipedia

  • Plasmalogen

    Encyclopedia entry covering structure, peroxisomal synthesis, membrane and antioxidant roles, rare synthesis disorders, and disease-linked depletion.

Examine

No Examine.com article for Plasmalogens was found.

ConsumerLab

Systematic Reviews

No systematic reviews or meta-analyses for Plasmalogens were found on PubMed as of August 23, 2026.

Mechanism of Action

Plasmalogens are membrane fats with a vinyl-ether bond (a carbon–carbon double bond next to oxygen) at the first carbon of glycerol. Ethanolamine plasmalogens concentrate in myelin and synapses; choline plasmalogens are enriched in heart muscle. Synthesis begins in peroxisomes: GNPAT (glyceronephosphate O-acyltransferase, the first committed ether-lipid enzyme) and AGPS (alkylglycerone phosphate synthase) build an alkyl backbone, with FAR1 (fatty acyl-CoA reductase 1) supplying fatty alcohols. The endoplasmic reticulum finishes the molecule; PEDS1 (plasmanylethanolamine desaturase 1, also called TMEM189) inserts the vinyl double bond.

The vinyl-ether changes membrane packing, which favors curvature, vesicle fusion, and neurotransmitter release. The second carbon typically carries DHA (docosahexaenoic acid, an omega-3 fat) or arachidonic acid. That same vinyl-ether can intercept oxidants, which some researchers read as a sacrificial antioxidant role. A competing view holds that falling peroxisomal output and plasmalogen loss are upstream drivers of amyloid processing, tau pathology, and cholinergic decline, not mere downstream damage markers.

Oral alkylglycerols skip the peroxisomal steps. Intact dietary plasmalogens are partly broken down in the gut. The best-characterized synthetic precursor, PPI-1011, is not absorbed intact. Its target metabolite, ethanolamine plasmalogen 16:0/22:6, reaches peak serum levels about 48–53 hours after a dose, with a terminal half-life of about 63–86 hours in humans, supporting once-daily use. Animal work shows distribution into liver, adipose tissue, and brain. Cytochrome P450 enzymes are not the primary clearance path; unused material is largely excreted in feces.

Historical Context & Evolution

Plasmalogens were first flagged in the 1920s by the histochemical “plasmal” stain. The peroxisomal ether-lipid pathway was mapped later in the twentieth century. Essentiality became clear when RCDP (rhizomelic chondrodysplasia punctata, a severe developmental disorder caused by failed plasmalogen synthesis via PEX7 (peroxin 7, the peroxisomal import receptor for AGPS), GNPAT, or AGPS) produced bone, brain, lens, and heart defects.

In the 1990s and 2000s, postmortem Alzheimer’s brains showed ethanolamine plasmalogen loss in affected regions. Goodenowe et al. 2007 (Phenomenome Discoveries, later Prodrome Sciences) reported that serum plasmalogen deficiency tracked dementia severity across several cohorts and predicted decline years before diagnosis. That claim is associative; critics treat depletion as a consequence of oxidative stress and neurodegeneration rather than a cause.

Japanese groups led by Takehiko Fujino and the Japanese Plasmalogen Society, which promotes scallop-derived products, moved milligram oral extracts into randomized trials. In parallel, Dayan Goodenowe commercialized gram-scale alkylglycerol precursor oils (ProdromeNeuro), and Peter Meikle’s Baker Institute group studied ether lipids in cardiometabolic disease, including a small shark-liver-oil trial. Med-Life Discoveries advanced PPI-1011 as a pharmaceutical precursor for RCDP. In January 2026 the U.S. Food and Drug Administration (FDA) issued a warning letter to Prodrome Sciences USA, LLC stating that a dementia precursor-oil study had been run as an unapproved drug trial. The field has moved from membrane chemistry toward restoration experiments; that shift still rests on association plus small, often seller-funded trials, not large independent outcome studies.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: named cognitive scales and cardiometabolic laboratory markers have not been shown for supplementation in more than one independent trial.

Medium 🟩 🟩

Triglycerides, Free Cholesterol, and C-Reactive Protein with Alkylglycerol-Rich Oil

In a randomized, double-blind, placebo-controlled crossover study, 10 overweight or obese men took 4 g/day purified shark liver oil, an alkylglycerol source the body converts into plasmalogens, for 3 weeks. Plasma and white-cell ether lipids rose, and triglycerides, free cholesterol, and C-reactive protein (a blood inflammation marker) fell versus placebo (Paul et al., 2021). The trial was small, short, and used mixed marine oil rather than a vinyl-ether isolate; no cardiovascular events were measured.

Magnitude: After 3 weeks of 4 g/day alkylglycerol-rich oil in 10 men, triglycerides fell from 2.25 to 1.64 mmol/L and cholesterol from 5.36 to 4.98 mmol/L; high-sensitivity C-reactive protein fell from 2.70 to 1.62 mg/L (Paul et al., 2021).

Anger, Hostility, and Fatigue Scores

A 4-week trial in 40 male college athletes found lower anger-hostility and fatigue-inertia scores with 2 mg/day scallop plasmalogen versus placebo. Overall mood disturbance was only marginally different; physical performance did not change. Young-athlete mood is not a dementia endpoint.

Magnitude: After 4 weeks of 2 mg/day in 40 male athletes, anger-hostility T-scores (standardized scores scaled so that 50 is typical) fell 4.3 points more than placebo (95% CI (confidence interval, the range likely to contain the true difference) −7.0 to −1.6; p = 0.003, how likely that difference would appear if there were no real effect) and fatigue-inertia T-scores fell 5.5 points more (−9.2 to −1.8) (Fujino et al., 2022).

Low 🟩

Cognitive Function ⚠️ Conflicted

The largest trial found no Mini-Mental State Examination difference versus placebo at 24 weeks, with possible memory-scale gains in women and younger mild-Alzheimer subgroups. One healthy-adult trial reported a composite-memory gain. A precursor-oil series was uncontrolled. Net reading: small subgroup-limited signal, not confirmed treatment.

Magnitude: No significant Mini-Mental State Examination difference versus placebo at 24 weeks in the 328-person trial (Fujino et al., 2017); a 12-week healthy-adult trial reported a 6.7-point composite-memory gain (Watanabe et al., 2020).

Mobility in Cognitively Impaired Adults

An unblinded 4-month DHA-alkylglycerol oil series (900–3,600 mg/day) in 22 people reported mobility gains in 12, no change in 5, and decline in 4. Authors sell the oil. Frontiers posted a January 2026 Expression of Concern on this paper.

Magnitude: 12 of 21 evaluated participants improved mobility measures in an uncontrolled 4-month precursor-oil series; no placebo-controlled mobility figure exists (Goodenowe et al., 2022).

Parkinson’s Clinical Symptoms

Ethanolamine plasmalogen is low in Parkinson’s red cells. A 24-week open-label series in 10 people reported improved clinical symptoms after oral scallop plasmalogen. Precursor oils protected dopamine neurons in MPTP (a toxin used to model parkinsonism) mice; no blinded motor-outcome trial exists.

Magnitude: Not quantified in available studies. The n=10 open-label series reported clinical improvement without a published motor-score change (Mawatari et al., 2020).

Speculative 🟨

Longer Life from Supplementation

Low circulating plasmalogens associate with dementia severity and coronary disease in observational work, but no supplementation trial has measured mortality or lifespan. The basis is association and mechanism only.

Benefit-Modifying Factors

  • Rare synthesis-gene variants: Pathogenic GNPAT, AGPS, PEX7, or FAR1 variants cause RCDP and profound plasmalogen deficiency. That is a pharmaceutical-precursor problem, not a milligram-extract consumer protocol.

  • Baseline circulating plasmalogens: Observational work ties lower blood ethanolamine plasmalogens to worse cognition and coronary stenosis. In the 22-person precursor-oil series, baseline DHA-plasmalogen did not predict who improved.

  • Sex: The 328-person scallop trial’s Wechsler Memory Scale-Revised signal concentrated in women with mild Alzheimer’s. A plasmalogen-plus-elastin trial likewise reported higher memory-scale scores in female strata (Yamada et al., 2024).

  • Pre-existing cognitive impairment: Human outcome trials cluster in mild Alzheimer’s, mild cognitive impairment, or self-reported forgetfulness. Healthy young adults have not shown cognitive gains; mood changes in athletes are a different endpoint.

  • Age: Circulating and brain plasmalogens fall with age, especially after midlife. In the large scallop trial, memory-scale between-group differences were clearer below age 77 than in older mild-Alzheimer participants.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: documented adverse events have not been replicated as serious clinical endpoints across more than one trial.

Medium 🟥 🟥

Gastrointestinal Upset with High-Dose Oil Precursors

In the first-in-human randomized trial of PPI-1011 (10–100 mg/kg single doses; 75–100 mg/kg/day for 14 days), all treatment-emergent adverse events were mild and resolved without intervention. The most common events were gastrointestinal in both precursor and placebo arms, consistent with an oil vehicle. Med-Life Discoveries, which is developing PPI-1011 as a drug, sponsored the study. Milligram marine capsules in Japanese trials did not generate a similar signal.

Magnitude: Not quantified in available studies. Mild gastrointestinal events occurred in both oil-precursor and placebo arms, and the paper does not isolate a plasmalogen-specific incidence from the oil vehicle (Smith et al., 2025).

Low 🟥

Source-Organism Allergy

Scallop-derived products exclude people with scallop allergy in trial protocols. Ascidian (Halocynthia roretzi), chicken, and shark oils carry analogous source-protein and marine-allergy issues. Reaction rates in unselected users have not been measured.

Magnitude: Not quantified in available studies. Scallop allergy was an exclusion criterion, not a counted event rate (Fujino et al., 2017).

Contaminant and Identity Risk in Marine Oils

Unpurified shark liver oil can carry variable squalene, fat-soluble vitamins, and environmental contaminants. The 4 g/day purified Alkyrol crossover did not report contaminant-related events, but crude oils are not equivalent to standardized vinyl-ether isolates. Long-term contaminant data for consumer plasmalogen brands are sparse.

Magnitude: Not quantified in available studies. The purified 3-week shark-liver-oil trial reported no contaminant adverse events and was too small to bound rare toxicities (Paul et al., 2021).

Speculative 🟨

Unknown Long-Term Safety

Human studies last weeks to a few months. Vinyl-ether lipids take part in lipid-peroxidation chemistry, including ferroptosis (iron-dependent membrane destruction) in cells. Chronic high-dose effects in people are unknown.

Risk-Modifying Factors

  • Rare peroxisomal genotypes: Biallelic GNPAT, AGPS, PEX7, or FAR1 disease is a medical-genetics setting. Over-the-counter extracts are not a substitute for investigational pharmaceutical precursors used in RCDP trials.

  • Low versus high baseline ether lipids: People with already-normal circulating plasmalogens have less remaining capacity to raise circulating species; the Phase 1 precursor study still raised the 16:0/22:6 species several-fold in healthy adults.

  • Sex: Cognitive-signal analyses in milligram trials favored women in some strata; sex-specific adverse-event rates have not been isolated.

  • Shellfish or marine-food allergy; active gastrointestinal disease: Source-organism allergy and pre-existing gut disease raise the chance that marine extracts or oil vehicles will not be tolerated.

  • Older age and polypharmacy: Trials enrolled adults through the mid-80s without a unique late-life toxicity signal, but older users more often take anticoagulants or lipid-lowering drugs that were trial exclusions.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel): Caution. The ProdromeNeuro open-label protocol excluded these users. Ether lipids sit near platelet-activating-factor chemistry; bleeding consequence is theoretical. Mitigate by avoiding unsupervised combination and watching for bruising.

  • Over-the-counter aspirin and NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen): Caution. Same theoretical platelet overlap as prescription antiplatelet drugs. Mitigate by watching for bruising if combined with high-dose oils.

  • Prescription lipid-lowering drugs (statins such as atorvastatin, ezetimibe, fibrates, evolocumab): Monitor. The PPI-1011 trial disallowed them. Alkylglycerol oil can move triglycerides and free cholesterol. Mitigate by repeating a fasting lipid panel after 3–6 weeks.

  • High-dose omega-3, krill, or other ether-rich oils: Additive. Krill and some fish oils already raise ether phospholipids. Consequence is overlapping gastrointestinal load and redundant DHA. Mitigate by not combining gram-scale oils without a plasmalogen panel.

  • Other marine-oil supplements: Caution. Combined contaminant and calorie load rises with concurrent shark, scallop, or mixed marine oils. Separate or drop redundant products.

Populations who should avoid Plasmalogens:

  • Known allergy to the source organism (scallop, sea squirt, shark, or chicken, depending on the product)
  • Pregnancy and lactation (no adequate human reproductive data; PPI-1011 trials excluded pregnant people)
  • People seeking an unapproved treatment for dementia, ALS (amyotrophic lateral sclerosis, a motor-neuron disease), or autism outside a regulated drug trial

Risk Mitigation Strategies

  • Match product to source allergy history: Choose ascidian, chicken, or synthetic precursor oils when scallop allergy is documented, which prevents marine-protein anaphylaxis (a severe, rapid allergic reaction) from the wrong extract.

  • Start milligram extracts before gram-scale oils: Japanese capsules use 0.5–2 mg/day; precursor oils start near 900 mg and escalate. A low start limits oil-related gastrointestinal adverse events.

  • Take oils with food, not on an empty stomach: PPI-1011 was given non-fasting. Food reduces gastrointestinal events from oil vehicles.

  • Prefer purified, tested marine isolates: Use lots with plasmalogen content, oxidation markers, and heavy-metal screens, which bounds contaminant and identity risk in unstandardized shark or mixed oils.

  • Keep high-dose oil courses short: Human studies last weeks to a few months. Stopping gram-scale oils after a trial-like window limits unknown chronic vinyl-ether peroxidation risk.

Therapeutic Protocol

  • Milligram marine-extract approach (Fujino / Japanese Plasmalogen Society; Sunsho ascidian products): 0.5–2 mg/day oral purified plasmalogen, usually once daily for 12–24 weeks in trials. This is not framed here as the default.

  • Gram-scale alkylglycerol-oil approach (Goodenowe / ProdromeNeuro): 900 mg/day for a month, then 1,800 mg, then 3,600 mg (about 1–4 mL oil) over 4 months in the open-label series.

  • Purified shark-liver-oil alkylglycerols (Baker Institute / Alkyrol): 4 g/day for 3 weeks in the crossover lipidomics trial. A cardiometabolic research protocol, not a cognition protocol.

  • Investigational PPI-1011 (Med-Life Discoveries): Once-daily oral oil at 75–100 mg/kg in the multiple-dose Phase 1; not a consumer supplement. Target metabolite half-life about 63–86 hours.

  • Time of day: Japanese safety and sleep protocols used morning dosing; high-dose oils were given non-fasting. Once-daily use fits the long metabolite half-life; splitting milligram capsules is optional, not required.

  • Genetics and dose choice: Rare GNPAT, AGPS, or PEX7 disease belongs in specialist precursor trials. Common GNPAT p.D519G is an iron-overload modifier. APOE4 (apolipoprotein E epsilon-4, an Alzheimer’s-risk gene variant) lacks genotype-specific dosing trials.

  • Sex: Women with mild Alzheimer’s drove part of the milligram-trial memory-scale signal; protocols themselves were not sex-stratified.

  • Age: Milligram trials enrolled ages 60–85; precursor-oil cognitive work included younger cognitively impaired adults. Older users have lower baseline levels but weaker subgroup signals above 77 in one trial.

  • Baseline ether-lipid panel: A pre-dose plasmalogen panel documents deficiency and later rise. Clinical response in the 22-person oil series did not track baseline DHA-plasmalogen.

  • Pre-existing disease: Mild cognitive impairment and mild Alzheimer’s dominate outcome data. Young healthy cognition is not a supported use case.

Discontinuation & Cycling

  • Duration: Protocols treat plasmalogens as ongoing replacement for an age-related decline, not a short antibiotic-style course. Trials themselves lasted 4–24 weeks.

  • Withdrawal: No withdrawal syndrome is described after milligram extracts or precursor oils. Blood levels fall as membranes turn over.

  • Tapering: Not required for milligram capsules. High-dose oils can be stepped down over 1–2 weeks to limit gastrointestinal rebound from abrupt oil cessation, by analogy with other oil supplements, not from plasmalogen-specific taper trials.

  • Cycling: No evidence that cycling preserves efficacy. The biochemical goal is sustained repletion, so on/off cycling works against that goal.

  • After stopping: Repeat a plasmalogen panel 4–8 weeks after the last dose if the aim was to confirm that circulating species were product-dependent.

Sourcing and Quality

  • Form matters: Consumer products are milligram vinyl-ether isolates (scallop, ascidian, or chicken), gram-scale alkylglycerol precursor oils, or mixed shark liver oil. They are not interchangeable doses.

  • Third-party testing: Lot-level plasmalogen or alkylglycerol content, oxidation markers, and heavy-metal screens are the usual quality markers. ConsumerLab’s plasmalogen piece is an effectiveness Q&A, not a brand-by-brand product review.

  • Acid-labile vinyl-ether: Stomach acid can break the defining bond. Oil-filled capsules and precursor alkylglycerols are used to improve delivery; plain powder is a weaker choice.

  • Brands in the literature: Prodrome Sciences (precursor oils; FDA warning letter January 2026), Daiwa Brain Health / Hokkaido scallop oil, Sunsho/Halocynthia extracts, Japanese Plasmalogen Society scallop isolates, and Alkyrol purified shark liver oil. Several trial sponsors sell the product under study.

  • Shark and marine sustainability: Shark-derived alkylglycerols raise ecological and contaminant issues that scallop, ascidian, algal-alkyl, or synthetic precursors do not share in the same way.

Practical Considerations

  • Time to effect: Blood ether lipids move within days to 2 weeks on precursor oils. Cognitive or mood scales in milligram trials were read at 4–24 weeks. Mobility changes in the open-label oil series were assessed over 4 months.

  • Common pitfalls: Treating milligram and gram-scale products as equivalent; combining krill, fish oil, and precursor oils; reading observational “low plasmalogen, high dementia” papers as proof that capsules extend lifespan; using seller-run dementia studies as if they were independent Phase 3 trials.

  • Regulatory status: Sold as dietary supplements or foods, not FDA-approved drugs. An FDA warning letter (8 January 2026) held that ProdromeNeuro oil in a dementia protocol was an investigational drug requiring an IND (Investigational New Drug application).

  • Cost: Gram-scale precursor oils are often cited near $100–200 per month. Milligram marine capsules are usually cheaper. PPI-1011 is not a retail product.

Interaction with Foundational Habits

  • Sleep: Direct, possible. A 2 mg/day athlete trial showed a near-significant Athens Insomnia Scale improvement at 2 weeks. A 12-week 1 mg/day sleep trial (NCT06907537) has completed without posted results. Evening high-dose oils may bother people who reflux.

  • Nutrition: Direct, potentiating. Dietary plasmalogens come from marine animals, not plants. Ether-lipid-rich meals and milligram extracts can add; gram-scale oils already supply substantial fat calories. Pairing with DHA-rich fish is biochemically coherent, not proven synergistic.

  • Exercise: Indirect, none established. The athlete trial found no physical-performance difference. The open-label oil series reported sit-to-stand and walk-test gains in some cognitively impaired adults, which may reflect function rather than training adaptation.

  • Stress management: Indirect, possible. Lower anger-hostility and fatigue scores in athletes could reflect membrane or inflammatory tone, not a cortisol-pathway drug effect. No named cortisol trial exists.

Monitoring Protocol & Defining Success

Before starting, a fasting ether-lipid panel (ethanolamine and choline plasmalogens, including DHA-containing species) documents whether circulating levels are low for the laboratory’s age-matched reference and sets a personal baseline. The same draw can include triglycerides and high-sensitivity C-reactive protein, because alkylglycerol oils have moved those markers. When memory is the reason for interest, add one named cognitive scale (Mini-Mental State Examination or Montreal Cognitive Assessment). Repeat the plasmalogen panel and lipids at 4 weeks, again at 12 weeks, then every 6–12 months if use continues. Repeat cognitive scales at 12–24 weeks.

Success is a clear rise in the targeted circulating plasmalogen species plus, where relevant, a pre-specified change on the same cognitive or mobility test used at baseline. No rise after 4 weeks of a documented dose implies a product, absorption, or adherence problem.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood ethanolamine and choline plasmalogens No established functional range; track change from personal baseline and any age-matched lab reference Confirms the product raises circulating species Fasting lipidomics; vendor panels (including commercial “prodrome” tests) are not standardized across labs
Fasting triglycerides Often <100 mg/dL in functional practice Alkylglycerol oil lowered triglycerides in one small trial 8–12 h fast; conventional <150 mg/dL
High-sensitivity C-reactive protein Often <1.0 mg/L functionally Same trial lowered this inflammation marker Skip during acute infection; conventional <3.0 mg/L
Mini-Mental State Examination or Montreal Cognitive Assessment Change from personal baseline; no plasmalogen-specific target Named scales used in human trials Same form, similar time of day

Qualitative markers:

  • Memory for names, recent events, and verbal lists
  • Mental stamina and subjective mental clouding
  • Anger, irritability, and residual fatigue
  • Gait speed, sit-to-stand ease, and fine-motor confidence
  • Sleep onset and night awakening, especially in the first 4 weeks

Emerging Research

  • Healthy-adult verbal memory: A 12-week scallop-plasmalogen trial reported a 10.1-point verbal-memory difference versus placebo (p = 0.042) in middle-aged adults (Fukuchi et al., 2026). Sponsor-run; not in PubMed at review time. Replication would strengthen, failure would weaken, that case.

  • Sleep protocol: NCT06907537 (completed; n = 44; Orthomedico) tested 1 mg/day plasmalogen for 12 weeks on insomnia-scale endpoints. Positive results would extend the athlete sleep signal; a null result would confine mood/sleep claims to one small trial.

  • Longer safety of milligram extracts: NCT06715475 (active, not recruiting; n = 24) is a 12-week 1 mg/day safety verification with blood and urine monitoring. It can bound common laboratory shifts but cannot settle rare or multi-year harm.

  • Pharmaceutical precursor path: NCT05969977 and the published Phase 1 (Smith et al., 2025) show several-fold rises in PlsEtn (ethanolamine plasmalogen) 16:0/22:6 at 75–100 mg/kg/day. RCDP efficacy data, if generated, would test whether restoring these fats changes function when synthesis is genetically blocked.

  • Independent-funding gap: Nearly all human outcome trials are tied to product sponsors (Japanese Plasmalogen Society, Prodrome Sciences, Sunsho, B&S, Med-Life Discoveries). A large, seller-independent cognition or cardiovascular-outcome trial remains the result that would most change the present reading, in either direction.

Conclusion

Plasmalogens are specialized membrane fats that decline with age and run low in dementia and coronary disease. Raising them is possible. Milligram marine extracts and gram-scale precursor oils both raise blood levels of these fats, and the precursor route can do so several-fold. What that change does for thinking, mood, walking, or heart-related blood fats is much less settled. The largest blinded milligram trial did not improve the main memory test, with possible benefit limited to subgroups. Smaller trials report modest memory or mood shifts, and a tiny precursor-oil study improved triglycerides and a blood inflammation marker. None of those outcomes has been repeated in a large independent trial.

Safety in short studies has been uneventful aside from gastrointestinal adverse events with high-dose oils, but products are not interchangeable, and source organisms create allergy risk. Much of the human evidence comes from organizations that sell the products under study — the Japanese Plasmalogen Society promotes scallop extracts its affiliates sell — and a 2026 U.S. regulator letter to one manufacturer underscores that disease-treatment claims sit outside supplement rules. For a longevity-focused adult, plasmalogens remain a biologically coherent, still-unproven restoration strategy whose strongest signal is higher blood levels of these fats, not proven extra years of healthy life.

Top - Benefits - Risks - Protocol